Comprehensive chronic lymphocytic leukemia diagnostics by combined multiplex ligation dependent probe amplification (MLPA) and interphase fluorescence in situ hybridization (iFISH)

Eyad Alhourani¹, Martina Rincic¹,², Moneeb AK Othman¹, Beate Pohle¹, Cordula Schlie¹, Anita Glaser¹ and Thomas Liehr¹*

Abstract

Background: Banding-karyotyping and metaphase-directed-fluorescence-in-situ hybridization (FISH) may be hampered by low mitotic index in leukemia. Interphase FISH (iFISH) is a way out here, however, testing many probes at the same time is protracted and expensive. Here multiplex-ligation-dependent-probe-amplification (MLPA) was used retrospectively in chronic lymphocytic leukemia (CLL) samples initially studied by banding cytogenetics and iFISH. Detection rates of iFISH and MLPA were compared and thus a cost-efficient scheme for routine diagnostics is proposed.

Results: Banding cytogenetics was done successfully in 67/85 samples. DNA was extracted from all 85 CLL samples. A commercially available MLPA probe set directed against 37 loci prone to be affected in hematological malignancies was applied. Besides, routine iFISH was done by commercially available probes for following regions: 11q22.3, 12p11.2-q11.1, 13q14.3, 13q34, 14q32.33 and 17p13.1. MLPA results were substantiated by iFISH using corresponding locus-specific probes.

Aberrations were detected in 67 of 85 samples (~79%) applying banding cytogenetics, iFISH and MLPA. A maximum of 8 aberrations was detected per sample; however, one aberration per sample was found most frequently. Overall 163 aberrations were identified. 15 of those (~9%) were exclusively detected by banding cytogenetics, 95 were found by MLPA (~58%) and 100 (~61%) by routine iFISH. MLPA was not able to distinguish reliably between mono- and biallelic del(13)(q14.3q14.3), which could be easily identified as well as quantified by routine iFISH. Also iFISH was superior to MLPA in samples with low tumor cell load. On the other hand MLPA detected additional aberrations in 22 samples, two of them being without any findings after routine iFISH.

Conclusions: Both MLPA and routine iFISH have comparable detection rates for aberrations being typically present in CLL. As MLPA can detect also rare chromosomal aberrations it should be used as an initial test if routine cytogenetics is not possible or non-informative. Still iFISH should be used additionally to distinguish mono- from biallelic deletions and also to determine rate of mosaicism for 13q14.2 to 13q14.3. In case MLPA is negative the corresponding CLL samples should be tested at least by iFISH using the standard probe set to.

Keywords: Chronic lymphocytic leukemia (CLL), Chromosomal aberrations, Multiplex ligation-dependent probe amplification (MLPA), Fluorescence in situ hybridization (FISH)
Background

Chronic lymphocytic leukemia (CLL) is considered as the most common adult leukemia in Western countries with an estimated incidence of 5.8 in men and of 3.0 in women per 100,000 individuals and per year. It predominantly affects persons with more than 50 years of age [1,2]. A hallmark of CLL is the presence of cytogenetic abnormalities; the latter help to estimate a patient's prognosis more accurately and also may provide insights into disease pathogenesis [3]. However, banding cytogenetics can only detect aberrations in ~30% of CLL samples [4]. Still, according to molecular (cyto)genetic data the major recurrent aberrations are:

(i) Deletions in 13q14 (50-60% of the samples) associated with a good prognosis, as are deletions in 14q32:33 (12-15% of the samples);
(ii) Trisomy 12 (15-25%) associated with intermediate prognosis; and
(iii) Deletions in 11q22 (ATM) (10-20%) or 17p13 (TP53) (5-10%) and/or recurrent balanced translocations go together with adverse prognosis [4-9];
(iv) Less frequently observed aberrations in CLL are deletions in 6q associated with intermediate prognosis, 9p21 and 10q23, total or partial trisomies of chromosomes 3, 8, 18, or 19, and duplications in 2p24, the prognostic significance for these aberrations is unknown [1,10,11].

These aberrations were either detected applying cytogenetics and/or interphase fluorescence in situ hybridization (iFISH) [3] or more recently multiplex ligation-dependent probe amplification (MLPA) [7]. While iFISH provides information only for a limited number of genomic targets at the same time [1,5,7] MLPA can detect copy number alterations, methylation pattern changes and/or even point mutations simultaneously in multiple target regions [7,12]. Still iFISH can more reliably detect low level mosaics and mosaics of mono- and biallelic deletions [13].

In this study the efficiency of MLPA was compared with yet in our lab routinely performed cytogenetic and iFISH diagnostics of CLL. Based on the obtained results a new diagnostic scheme is proposed combining MLPA and iFISH leading to a more comprehensive characterization of each individual sample.

Results

85 samples of patients suffering from CLL (Additional file 1: Table S1 and Additional file 2: Table S2) were studied here. Overall, including results from all here applied tests, chromosomal aberrations were detected in 70/85 (~85%) of the studied CLL-samples (Additional file 1: Table S1 and Additional file 2: Table S2). As summarized in Figure 1 between 0 and 8 aberrations were detectable per case. One chromosomal rearrangement per sample could be found most often (40%), followed by no aberration at all and three aberrations per sample. Four or more aberrations per sample were found in less than 10% of the cases.

Overall, 163 aberrations were detected in the 85 studied samples (Table 1, Additional file 2: Table S2). Cytogenetics revealed aberrant karyotypes in 15 (~22%) of the 67 samples where corresponding analyses was successful (Additional file 1: Table S1). In parts the cytogenetic findings could be substantiated by iFISH and or MLPA. As no corresponding probes were included neither in routine iFISH nor in MLPA, 15 (~9%) of the 163 detected aberrations were found additionally by cytogenetics (Table 2). Interestingly, in sample 57 which presented with 5 chromosomal aberrations after banding cytogenetics no aberrations could be detected at all by iFISH or by MLPA. Other samples gave either no, a normal cytogenetic result or a result which also was confirmed by MLPA and/or iFISH (Additional file 1: Table S1).

Concerning the detection rates, the applied MLPA test found ~58% and routine iFISH ~61% of the 163 aberrations (Table 1, Additional file 2: Table S2). del(13)(q14.3q14.3) was most frequently found, i.e. in ~28% of the samples), followed by del(11)(q22.3q22.3) in ~9%, del(14)(q32q32) in ~8%, and del(13)(q14.2q14.2) and del(17)(p13.1p13.1) in ~6% of the samples, each.

Discordant results of MLPA and routine iFISH were in parts due to the different target regions covered by the tests; thus e.g. del(14)(q32q32) were only detectable by routine iFISH. On the other hand, MLPA detected additional aberrations in 22 samples, three of the patients being without any aberrant findings according to routine iFISH (Additional file 2: Table S2, cases 68–70).

In Table 3 thirteen samples are listed, which had low level mosaic aberrations based on routine iFISH and were not picked up by MLPA. In contrary in Table 4 twelve other samples with similar low level mosaics are listed, which were picked up by MLPA.

![Figure 1](http://www.molecularcytogenetics.org/content/7/1/79)
Table 5 highlights 19 samples which were detected as carrying deletions in 13q14.2 and/or 13q14.3 according to MLPA and iFISH. Still iFISH revealed that there was a mix of monoallelic and biallelic deletion or only biallelic deletion, which could not always be detected by MLPA (Additional file 2: Table S2). Only such cases which had 100% biallelic deletions could be identified undoubtedly (e.g. sample 30); others showed biallelic deletions in MLPA but were indeed a mix of mono- and biallelic ones.

Finally, three copy number alterations found by MLPA could not be substantiated by additional iFISH studies (samples 65–67; Additional file 2: Table S2).

In Figure 2 a flow is suggested how a CLL-characterization could be performed most comprehensively and straightforward. Figure 3 shows how cases would have been grouped if only cytogenetics, only MLPA or only iFISH would have been done. Tables 6, 7 and 8 highlights how a step by step characterization and corresponding new results of would change the prognosis of the 95 studied cases.

Discussion
When diagnostic screening for acquired genetic alteration in hematological malignancies is to be done, banding cytogenetics is still the gold standard, as it enables Table 2 Aberrations only detected by banding cytogenetics in 9 samples of the present study

Sample number | Aberration only visible in GTG-banding [%]
--- | ---
1 | del(5)(p15.3)(p15.3)
32 | -Y[44]
34 | -Y[50]
38 | t(3;7)(p21;7)[43]
41 | -Y[80]
57 | der(1)t(1;4)(q12;q21)[90]
58 | der(1)t(1;4)(q12;q21)[90]
61 | t(3;7)(p21;7)[22]
70 | ?addl(q)(q4)[50]

Table 3 Detailed results in samples contributing to the discordant results of MLPA and iFISH marked with asterisk * in Table 1

Affected regions | Genes | Sample number | iFISH mosaik [%]
--- | --- | --- | ---
de1(11)(q22.3;q22.3) | ATM | 1 | 30
+12 | ETV6, CCND2, MDM2 | 3 | 15
+12 | ETV6, CCND2, MDM2 | 4 | 31

de1(13)(q14.3)(q14.3) | DLEU1, DLEU2, MIR15A | 5 | 18

de1(13)(q14.3)(q14.3) | DLEU1, DLEU2, MIR15A | 6 | 10

de1(13)(q14.3)(q14.3) | DLEU1, DLEU2, MIR15A | 7 | 10.5

de1(13)(q14.3)(q14.3) | DLEU1, DLEU2, MIR15A | 8 | 12

de1(13)(q14.3)(q14.3) | DLEU1, DLEU2, MIR15A | 9 | 18.5

de1(13)(q14.3)(q14.3) | DLEU1, DLEU2, MIR15A | 10 | 25

de1(13)(q14.3)(q14.3) | DLEU1, DLEU2, MIR15A | 11 | 34

de1(13)(q14.3)(q14.3) | DLEU1, DLEU2, MIR15A | 12 | 34

de1(17)(p13.1)(p13.1) | TP53 | 13 | 11.5

Those with * are detailed in Table 2, those with ** in Table 4. Those with + could either not be tested in iFISH due to lack of corresponding probe or, in the two of the tested samples MLPA could not be confirmed by iFISH (routine and confirmatory together), most likely due to too large FISH-probe size.
the untargeted search for gross chromosomal aberrations [14]. Malignant CLL cells derived from bone marrow are known to have a low mitotic index and in many cases only cytogenetically normal cells can be analyzed [4]. Thus, iFISH and MLPA are routinely applied additionally to or even as a replacement in tumor cytogenetics of CLL [7,15].

In this study, after directed diagnostics for 37 genetic loci (MLPA and routine iFISH together), still ~18% of the samples remained without an identified tumor marker. As highlighted by samples 32, 34, 41, 36 (see also [16]), 38, 57, 58, 61 and 70 this can be due to unusual, not by targeted routine tests covered chromosomal aberrations; besides submicroscopic aberrations like point mutations [2] could be present in those ‘normal’ samples. Interestingly, in over 40% of the studied cases more than only one chromosomal aberration was identified (Figure 1). This may reflect in parts the slow progress of CLL. I.e. the malignancy is detected after acquiring multiple aberrations and not as early as e.g. chronic myelogeneous leukemia (CML), which is already connected with severe clinical signs when only a t(9;22) is found, which is the only aberration in majority of the CML-cases [17].

As mentioned above, MLPA and routine iFISH are targeted tests, both. As they cover in parts different loci it was not unexpected that they have different detection rates. However, one would expect that iFISH technique underestimates the genomic complexity in CLL [1]. Still it is striking that the routine iFISH test found 61% of the 163 aberrations while MLPA only detected 58%, even though routine iFISH applied only 5 probes and MLPA had more than 7 times more, i.e. 37 target regions.

Concerning detection of low level mosaics (10% up to 36% of the cells being aberrant) this study showed that there are about alike amounts of cases being detectable and being missed by MLPA (Tables 3 and 4). There were cases detectable by MLPA with aberrant cell clone sizes down to ~10% according to iFISH (sample 16) and such being not detectable (samples 6, 7, and 8). To the best of our knowledge there are only few previous [18-20] and no systematic studies for the detection rates of low level mosaic in MLPA. Véronèse et al. [7] suggested that all false-negative cases occur in samples with only 12-21% of aberrant cells; thus they considered MLPA detection to be reliable when the fraction of aberrant cells is 25-30%, which is definitely less sensitive than iFISH detection. Overall, this problem has to be kept in mind when doing MLPA exclusively in routine diagnostics.

Still, the findings of this study are in concordance with Stevens-Kroef et al. [21] who claimed an almost perfect correlation between MLPA and iFISH, as long as identical genetic regions are tested in MLPA and iFISH. However, bi- and monoallelic deletions coming together in one sample are not considered in this kind of comparison. Still, all apart from three MLPA findings not detectable in the

### Table 4 Detailed results in samples with concordance of MLPA and routine iFISH results but mosaic rates below 40% according to iFISH

| Affected regions     | Genes      | Sample number | iFISH mosaic [%] |
|----------------------|------------|---------------|-----------------|
| del(11)(q22.3q22.3)  | ATM        | 14            | 235             |
| del(11)(q22.3q22.3)  | ATM        | 15            | 24              |
| del(11)(q22.3q22.3)  | ATM        | 16            | 11              |
| del(13)(q14.3q14.3)  | DLEU1, DLEU2, MIR1SA | 1   | 30              |
| del(13)(q14.3q14.3)  | DLEU1, DLEU2, MIR1SA | 2   | 18              |
| del(13)(q14.3q14.3)  | DLEU1, DLEU2, MIR1SA | 4   | 20              |
| del(13)(q14.3q14.3)  | DLEU1, DLEU2, MIR1SA | 14  | 34              |
| del(13)(q14.3q14.3)  | DLEU1, DLEU2, MIR1SA | 17  | 20              |
| del(17)(p13.1p13.1)  | TP53       | 1             | 16              |
| del(17)(p13.1p13.1)  | TP53       | 12            | 21              |
| del(17)(p13.1p13.1)  | TP53       | 18            | 19              |
| del(17)(p13.1p13.1)  | TP53       | 19            | 36              |

### Table 5 Combination of biallelic and/or monoallelic deletion del(13)(q14.2q14.2) and del(13)(q14.3q14.3) – which is not clearly resolved by MLPA

| Sample number | iFISH mosaic [%] del(13)(q14.2q14.2) | iFISH mosaic [%] del(13)(q14.3q14.3) |
|---------------|--------------------------------------|--------------------------------------|
|               | Monoallelic deletion | Biallelic deletion | Monoallelic deletion | Biallelic deletion |
| 2             | 0 | 0 | 18 | 14 |
| 4             | 45 | 0 | 20 | 0 |
| 12            | 52 | 38 | 34 | 0 |
| 13            | 0 | 0 | 0 | 98.5 |
| 20            | 0 | 0 | 0 | 94 |
| 21            | 50 | 30 | 0 | 91 |
| 22            | 0 | 0 | 5 | 75 |
| 23            | 0 | 0 | 5 | 81 |
| 24            | 36 | 41 | 16 | 71 |
| 25            | 66 | 21 | 18 | 77 |
| 26            | 0 | 0 | 25 | 65 |
| 27            | 34 | 27 | 36.5 | 24 |
| 28            | 0 | 0 | 81 | 7 |
| 29            | 58 | 24 | 86 | 9 |
| 30            | 0 | 0 | 0 | 100 |
| 54            | 41 | 39 | 97 | 0 |
| 55            | 73 | 5 | 85 | 0 |
| 56            | 22 | 58 | 12 | 66 |
| 63            | 51 | 38 | 90 | 0 |
Figure 2 Suggestion how to proceed when doing MLPA as a primary test after GTG-banding: in case MLPA finds a tumor marker with adverse prognosis no further iFISH analyses is necessary. In case of an MLPA result suggesting intermediate, unclear or good iFISH for 3 to 6 target regions should be done. A probe for 6q may be also used; however, as case with a del(6q) are rare we would not recommend it at present as really indicated to be applied. According to the obtained results cases need to be regrouped. Finally, iFISH can be used to subclassify cases with good prognosis into such with favorable and unfavorable good prognosis.

Figure 3 Detection rates of cytogenetics, MLPA and iFISH as standalone approaches are depicted and compared with overall result combining all three tests as suggested in Figure 2; the corresponding results obtained in the 85 cases were aligned with and are expressed as the resulting prognostic relevance of the identified chromosomal aberrations.
Table 6 Samples from Additional file 2: Table S2 are listed according to the groups suggested in Figure 2

| Results according to MLPA | Adverse prognosis | Intermediate or unclear prognosis | Good prognosis including groups “favorable” and “unfavorable” | No aberrations |
|---------------------------|-------------------|---------------------------------|----------------------------------------------------------|----------------|
| Samples                   |                   |                                 |                                                          |                |
|                           | 1, 10, 12, 14, 15, 16, 17, 18, 19, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 | 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69 | 6, 7, 8, 9, 11, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 67, 67, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 |
| Number of samples per group (absolute) | 20 | 4 | 32 | 29 |
| Number of samples per group (percent) | 23.5 | 5 | 37.5 | 34 |

Samples marked with * have biallelic deletion in 13q14 as substantiated by iFISH or deletion of 13q14.2 and 13q14.3, thus going from favorable to unfavorable subgroup within good prognosis group after iFISH (see Table 7). Figures printed not bold and not in italics are case numbers; figures printed bold and in italics are absolute numbers of samples or same numbers in percent.

Table 7 Regrouping of samples from Table 6 after doing additional i-FISH as suggested in Figure 2

| Results according to MLPA | Adverse prognosis | Intermediate prognosis | Good prognosis “unfavorable” | Good prognosis “favorable” | No aberrations |
|---------------------------|-------------------|------------------------|-------------------------------|--------------------------|----------------|
| Samples                   |                   |                        |                                |                          |                |
|                           | 1*, 2*, 3*, 10, 12, 13, 14, 15, 16, 17, 18, 19, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 66, 67 | 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 66, 67 | 6, 7, 8, 9, 11, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 67 | 36, 57, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 |
| Number of samples per group (absolute) | 24 | 5 | 25 | 13 |
| Number of samples per group (percent) | 28 | 6 | 30 | 15 |

Samples marked with * have real(14)(q32.33), thus they have to go to the adverse prognosis group. Samples with deletion of 13q14.2 and 13q14.3 detected by MLPA and/or deletion of 13q14.3 in ≥70% of the nuclei detected by iFISH go to unfavorable subgroup within good prognosis group. Figures printed not bold and not in italics are case numbers; figures printed bold and in italics are absolute numbers of samples or same numbers in percent.
Table 8 Final result after including result of GTG-banding based on from Tables 6 and 7

| Results according to MLPA | Adverse prognosis | Intermediate or unclear prognosis | Good prognosis “unfavorable” | Good prognosis “favorable” | No aberrations |
|---------------------------|-------------------|----------------------------------|----------------------------|---------------------------|----------------|
| Samples                   | 1, 2, 3, 10, 12, 13, 14, 15, 16, 17, 18, 19, 24, 34, 35, 38, 39, 54, 57*, 58, 60, 61, 63, 64, 65, 70* | 20, 21, 22, 23, 25, 26, 27, 28, 29, 30, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 66, 67 | 6, 7, 8, 9, 11, 31, 32, 33, 40, 41, 42, 59, 69 | 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 |
| Number of samples per group (absolute) | 26 | 6 | 25 | 13 | 15 |
| Number of samples per group (percent) | 31 | 7 | 30 | 15 | 17 |

Samples marked with * have additional aberration not detectable by MLPA or routine iFISH. Figures printed not bold and not in italics are case numbers; figures printed bold and in italics are absolute numbers of samples or same numbers in percent.

cohort e.g. samples 2 and 13 go to “good prognosis”, samples 3 and 60 to “adverse prognosis” and sample 4 to “intermediate prognosis” group (Tables 6, 7 and 8).

Finally, 32 patients (Tables 6, 7 and 8) have been classified as ‘good prognosis’ after MLPA. Here, the same FISH probes as for normal MLPA result should be used for further subclassification (Figure 2). Again patients then may have to be moved to other prognostic groups if additional or low level mosaics are identified. Also it is known that CLL cases with del(13)(q14.2q14.2) go into unfavorable subgroup, as do cases with biallelic deletions in 13q14. Finally, del(13)(q14.3q14.3) detected in ≥70% of the cells are also an indication to group a patient in unfavorable subgroup of ‘good prognosis’ group [1,22]. Thus, further I-FISH studies are necessary also for patients with del(13)(q14.2q14.2) and/or del(13)(q14.3q14.3) in MLPA.

In case only MLPA and IFISH would have been done in the presently studied 85 patient still 3 samples would have been misclassified. Thus we suggest in Figure 2 still GTG-banding as the initial test for CLL diagnostics. Compared to a flow just applying banding cytogenetics and routine iFISH for diagnostics of CLL the introduction of the flow from Figure 2 would apply only 344 instead of 425 FISH-probes, i.e. 20% less.

Conclusion
The present study shows the importance of combining cytogenetics, molecular genetics and molecular cytogenetics to achieve a comprehensive characterization of acquired genetic alterations being present in CLL.

Methods
Patients and sample preparation
The present study included 85 samples of patients suffering from CLL (Additional file 1: Table S1 and Additional file 2: Table S2) diagnosed according to standard criteria [26]. The samples were obtained under informed consent of the corresponding patients and according to institutional ethical committee guidelines (Ethical committee of the Friedrich Schiller University Jena). DNA from lymphocytes was extracted by a commercial kit (Qiagen, Hilden, Germany) and was derived from different sources: 2 samples from heparinized bone marrow, 8 samples from heparinized blood, and 75 samples from cytogenetically prepared cells fixed in methanol/acetic acid (3:1) – 48 of them derived from bone marrow and 27 from blood (Additional file 1: Table S1).

GTG-banding and FISH analysis
The blood or bone marrow samples were stimulated with phorbol ester, i.e. 12-O-tetradecanoylphorbol-13-acetate (TPA) and cultivated for 96 hours, and a standard cytogenetic cell preparation following air drying method was done [27]. GTG-banding and iFISH analyses were routinely done in each sample following standard procedures [27,28]. In 67 samples chromosomes could be obtained from the material prepared.

For routine iFISH the following commercially available probe sets (Abbott/Vysis, Wiesbaden, Germany) were used: LSI p53/LSI ATM (in 17p13.1 and 11q22.3), LSI D13S319/LSI 13q34/CEP 12 (in 13q14.3, 13q34 and 12p11.1-q11.1), and LSI IGH dual color, break-apart probe (in 14q32.33).

Additionally, the following probes were used to validate and possibly confirm the results of MLPA:

- from Abbott/Vysis (Wiesbaden, Germany): LSI 13 (RB1 in 13q14.2), CEP 6 (D6Z1 in 6p11.1-q11.1), CEP 17 (D17Z1 in 17p11.1-q11.1) and CEP 18 (D18Z1 in 18p11.1-q11.1);
- from ZytoVision (Bremerhaven, Germany): ZytoLight *SPEC ALK Dual Color Break Apart (in 2p22.32 ~ 22.31), ZytoLight *SPEC NMYC/2q11 Dual Color (in 2q24.3 and 2q11), ZytoLight *SPEC MYB Dual Color Break Apart (in 6q23.3), ZytoLight *SPEC ESR1/CEN 6 Dual Color (in 6q25.1 and 6p11.1-q11.1), ZytoLight *SPEC CMYC/CEN 8 Dual Color (8q24.21 and 8p11.1-q11.1), ZytoLight *SPEC ETV6/RUNX1 Dual Color Dual Fusion (in 12p13.2 and 21q22.12); and
- BACPAC Resources Center (Oakland, USA): RP1-142 L7 in 6q21 (gene FYN), RP11-318A15 in 17q25.1 (gene LINC13D), RP11-346H17 in 18q21.2 (gene DCC), RP11-37D8 in 6q27 (gene SMOC2) and RP11-411B in 18p11.22 (gene RNMT).
Table 9 Loci addressed in the commercially available MLPA kit used in this study

| Targets | Loci         | Number of probes included in kit |
|---------|--------------|----------------------------------|
| MYCN   | 2p24.3       | 2                                |
| ALK    | 2p23.2 – 23.1| 1                                |
| MIR145 | 5q33.1       | 1                                |
| EBF1   | 5q33.3       | 2                                |
| MIR146A| 5q33.3       | 1                                |
| FYN    | 6q21         | 1                                |
| MYB    | 6q23.3       | 1                                |
| ESR1   | 6q25.1       | 1                                |
| SMCQ2  | 6q27         | 1                                |
| IKZF1  | 7p12.2       | 3                                |
| CDM6   | 7q21.2       | 1                                |
| RELN   | 7q22.1       | 1                                |
| MET    | 7q31.2       | 1                                |
| DPP6   | 7q36.2       | 1                                |
| MYC    | 8q24.21      | 2                                |
| MTAP   | 9p21.3       | 1                                |
| CDKN2A | 9p21.3       | 1                                |
| CDKN2B | 9p21.3       | 1                                |
| PAX5   | 9p13.2       | 2                                |
| PTEN   | 9p13.1       | 1                                |
| PTEN   | 10q23.31     | 1                                |
| ATM    | 11q22.3      | 4                                |
| ETV6   | 12p13.2      | 2                                |
| MDM2   | 12q15        | 1                                |
| CCND2  | 12p13.32     | 1                                |
| RB1    | 13q14.2      | 2                                |
| MIR15A | 13q14.3      | 1                                |
| DLEU1  | 13q14.3      | 1                                |
| DLEU2  | 13q14.3      | 1                                |
| TP53   | 17p13.1      | 4                                |
| UNC13D | 17q25.1      | 1                                |
| IKZF3  | 17q12        | 1                                |
| DCC    | 18q21.2      | 1                                |
| RNMT   | 18q21.2      | 1                                |
| CACNA1A| 19p13.13     | 1                                |
| CHMP2A | 19q13.43     | 1                                |
| RUNX1  | 21q22.12     | 2                                |

For each iFISH analysis, at least 100–200 interphase nuclei were examined per sample and FISH-probe.

MLPA analysis
MLPA was performed using SALSA MLPA probemix P377-A1 for Hematological Malignancies Kit from (MRG-Holland, Amsterdam, The Netherlands). The P377-A1 probemix kit contains probes for 37 genes covered by overall 52 probes, which have diagnostic or prognostic significant role in hematologic malignancies (see Table 9). MLPA was performed according to the manufacturer’s protocol, which includes three reaction phases: hybridization, ligation, and PCR. Finally, a capillary electrophoresis was used to separate and analyze MLPA PCR products. Genemarker software was used to analyze the peak areas of the MLPA PCR products, and the ratio was normalized to a healthy control. Threshold of detection was set at 0.65–1.35, to minimize the false positive cases.

Additional files

Additional file 1: Table S1. Gender, age and cytogenetic results of the studied cases/samples.
Additional file 2: Table S2. Aberrations detected in 85 CLL samples and by which method the corresponding aberrations could be detected.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
EA performed FISH experiments and drafted the paper; EA, MR and MAKO did the MLPA experiments, BP, CS and AG performed the banding cytogenetic analyses, and TL planned the study and finalized the paper. All authors read and approved the final submission.

Acknowledgments
Supported in parts by the KAAD and the DAAD.

Author details
1 Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Kollegienasse 10, D-07743 Jena, Germany.
2 Croatian Institute of Brain Research, Salata 12, 1000 Zagreb, Croatia.

Received: 19 September 2014 Accepted: 23 October 2014
Published online: 19 November 2014

References
1. Rodríguez-Vicente AE, Díaz MG, Hernández-Rivas JM: Chronic lymphocytic leukemia: a clinical and molecular heterogeneous disease. Cancer Genet 2013, 206:49–62.
2. Campregher PV, Hamerschlak N: Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice. Clin Lymphoma Myeloma Leuk 2014, 14:271–276.
3. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910–1916.
4. Quinto-Rivera F, Nocoria F, Rao PN: Frequency of 5'IGH deletions in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2009, 190:33–39.
5. Mayr C, Speicher MR, Kolfer DM, Buhmann R, Strehl J, Busch R, Hallek M, Wendtner CM: Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006, 107:742–751.
6. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T: Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping. Leukemia 2007, 21:2442–2451.
7. Vérонèle L, Tournilhac O, Combès P, Prie N, Pierre-Eymard E, Guézè R, Veyrat-Masson R, Bay JD, Vago P, Tchitkov A: Contribution of MLPA to routine diagnostic testing of recurrent genomic aberrations in chronic lymphocytic leukemia. Cancer Genet 2013, 206:19–25.
8. Yoon JH, Kim Y, Yahng SA, Shin SH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Kim DW, Lee JW, Min WS, Park CW, Lim J, Kim Y, Han K, Kim M, Cho SJ. Validation of Western common recurrent chromosomal aberrations in Korean chronic lymphocytic leukemia patients with very low incidence. Hematol Oncol 2013. doi:10.1002/hon.2103, in press.

9. Grepp PF, Smalley SA, Vavranatha DS, Frederick LS, Rabe KG, Sharma RG, Slager SL, Van Dyke DL, Shanafelt TD, Tschumper RC, Zent CS. Patients with chronic lymphocytic leukemia and clonal deletion of both 17p13.1 and 11q23.2 have a very poor prognosis. Br J Haematol 2013, 163:326–333.

10. Cuneo A, Rigolin GA, Biggeri R, De Angelis C, Veronese A, Cavazzini F, Barbieri A, Roberti MG, Tammissi E, Agostini P, Ciccio D, Mella Porta M, Tieghi A, Cavazzini L, Negri M, Castoldi G. Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. Leukemia 2004, 18:476–483.

11. Fabris S, Mosca L, Cutrona G, Lionetti M, Agnelli L, Ciceni G, Barbieri M, Maura F, Matis S, Colorno M, Gentile M, Recchia AG, Anna Pesce E, Di Raimondo F, Musolino C, Gobbi M, Di Renzo N, Mauro FR, Brugiatelli M, Ilarucci F, Lipari MG, Angrilli P, Consoli U, Fragasso A, Molica S, Festini G, Vincelli I, Cortelezzi A, Frederico M, Morabito F, et al. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. Ann J Hematol 2013, 88:24–31.

12. Hömig-Hölzel C, Savola S. Multiplex ligation-dependent probe amplification (MLPA) in tumor diagnostics and prognostics. Diagn Mol Pathol 2012, 21:195–206.

13. Liehr T, Karamysheva T, Merkas M, Brecevic L, Hamid AB, Ewers E, Mrasek K, Hömig-Hölzel C, Savola S. Different genetic mechanisms but equivalent poorer clinical outcome. Am J Hematol 2012, 88:97–100.

20. Al Zaabi EA, Fernandez LA, Sadek IA, Riddell DC, Greer WL. Multisite deletions in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal aberrations. Genes Chromosomes Cancer 2012, 51:881–889.

21. Halik M, Cheson BD, Cakydar T, Caldari G, Cappel D, Ghibri G, Döben H, Hillmen P, Keating MJ, Montserrat E, Rai R, Kipp TJ. International Workshop on Chronic Lymphocytic Leukemia: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008, 112:546–5456.

22. Clausen U, Michel S, Mühlig P, Westermann M, Grummt UW, Kummer-Hauschild K, Liefhe B. Demystifying chromosome preparation and the implications for the concept of chromosome condensation during mitosis. Cytogenet Genome Res 2002, 98:136–146.

23. Liefhe B, Cistaro H, Rubano S, Trifonov V, Maek S, Weise A, Kuechler A, Clausen U. Microdissection based high resolution multicolor banding for all 24 human chromosomes. Int J Mol Med 2002, 9:335–339.